Break the loop. Build a new future.
RESET is a clinical-stage neurotherapeutics company dedicated to the responsible development of investigational compounds and physician-supervised protocols for addiction recovery research.
Investigational compounds for authorized clinical research use only. Not for use outside of approved clinical protocols.
Designed for the brain. Built for breakthrough change.
RESET develops investigational compounds and protocols designed to help the brain heal, restore balance, and rebuild lives — within authorized clinical research and physician-supervised settings, with discipline at every layer.
Focus the Science
Neuroscience-led research targeting the pathways that support long-term change.
Trust the Process
GMP-aligned development, batch control, and ethical sourcing — built to the highest pharmaceutical standards.
Transform the Future
A new era of regulated neurotherapeutics, built responsibly with patients, families, and clinicians.
Four disciplines, one operating system.
RESET is built around four disciplines that together define what responsible development looks like in this category.
Science-Led Development
Decisions follow the evidence. Every compound and protocol is grounded in current neuroscience and the broader landscape of clinical research.
Clinical-Grade Formulations
Investigational compounds developed to recognised GMP frameworks — batch-controlled, traceable, and accountable.
Ethical & Responsible
Responsibly sourced, conservatively claimed, designed to be the most regulatable operator in the category.
Patient-Focused
Developed with patients, families, and clinicians at the centre. Compassion is a design constraint, not a marketing line.
RESET-01 — our first clinical research formulation.
RESET-01 is an investigational neurotherapeutic compound presented here for partnership and informational purposes only. It is not approved for therapeutic use; it is intended solely for authorized clinical research under physician-supervised protocols.
- Designation
- Clinical Research Formulation
- Count
- 30 Capsules
- Active
- 5 mg (illustrative)
- Setting
- Physician-supervised protocols only
RESET-01 is an investigational neurotherapeutic compound presented here for partnership and informational purposes. It is not approved for therapeutic use. RESET makes no claim as to the safety or efficacy of any compound. Use only within authorized clinical research and physician-supervised protocols.
Formulation
Clinical Grade
Built to the highest pharmaceutical standards — GMP-aligned, batch-controlled, fully traceable.
Neuroscience-Led
Targeting pathways that, in the broader scientific landscape, are associated with long-term behavioural change.
Compassion-Driven
Developed with patients, families, and clinicians — protocols designed to support whole-person recovery research.
Regulated Access
Authorized clinical research settings only. Not for use outside of approved clinical protocols.
A new era of regulated neurotherapeutics is beginning.
Addiction is the most under-built area in modern medicine. Existing tools leave the central biology of the addiction loop largely untouched. A new era of regulated neurotherapeutics is beginning — and RESET is building the infrastructure for lasting recovery.
Figures shown are estimated magnitudes pending a cited source; see compliance notes.
Build the regulated future of addiction recovery with us.
RESET works with clinical research partners, manufacturers, institutional investors, and strategic partners. The first credible, compliance-first operators will define this category. We are building it with discipline.
Compliance as the moat
The most regulatable operator holds the durable advantage in a regulated category.
Brand as infrastructure
Physician and institutional confidence is a real asset. RESET is engineered to earn it.
Optionality, not single-asset risk
A platform brand for the field; multiple investigational compounds and protocols can plug in.
This material is for informational purposes only and does not constitute an offer of securities, investment advice, or a solicitation in any jurisdiction. Forward-looking statements involve risk and uncertainty; outcomes in a regulated, pre-approval category cannot be assured.
Open a disciplined conversation.
RESET works with clinical research, manufacturing, and institutional partners. Tell us which you are and we will route your inquiry appropriately.
Direct channels
- Clinical & researchresearch@reset01.com
- Manufacturing & supplysupply@reset01.com
- Institutional & investorpartners@reset01.com
- Medical & regulatoryregulatory@reset01.com
Do not submit personal health information or medical questions through this form. Inquiries are handled for partnership, research, and institutional purposes only.